Comparison of a Whole-Brain Contrast-Enhanced 3D TSE T1WI versus Orbits Contrast-Enhanced 2D Coronal T1WI at 3T MRI for the Detection of Optic Nerve Enhancement in Patients with Acute Loss of Visual Acuity

References

1. 1.↵
   1. Petzold A,
   2. Wattjes MP,
   3. Costello F, et al

   . The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 2014;10:447–58 doi:10.1038/nrneurol.2014.108 pmid:25002105

   CrossRefPubMed
2. 2.↵
   1. Petzold A,
   2. Fraser CL,
   3. Abegg M, et al

   . Diagnosis and classification of optic neuritis. Lancet Neurol 2022;21:1120–34 doi:10.1016/S1474-4422(22)00200-9 pmid:36179757

   CrossRefPubMed
3. 3.↵
   1. Dutra BG,
   2. da Rocha AJ,
   3. Nunes RH, et al

   . Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis. Radiographics 2018;38:169–93 doi:10.1148/rg.2018170141 pmid:29320331

   CrossRefPubMed
4. 4.↵
   1. Marques IB,
   2. Matias F,
   3. Silva ED, et al

   . Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 2014;21:583–86 doi:10.1016/j.jocn.2013.06.013 pmid:24231563

   CrossRefPubMed
5. 5.↵
   1. Wilhelm H,
   2. Schabet M

   . The diagnosis and treatment of optic neuritis. Dtsch Arztebl Int 2015;112:616–25; quiz 626 doi:10.3238/arztebl.2015.0616 pmid:26396053

   CrossRefPubMed
6. 6.↵
   1. Thompson AJ,
   2. Banwell BL,
   3. Barkhof F, et al

   . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73 doi:10.1016/S1474-4422(17)30470-2 pmid:29275977

   CrossRefPubMed
7. 7.↵
   1. Filippi M,
   2. Rocca MA,
   3. Ciccarelli O, et al

   ; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15:292–303 doi:10.1016/S1474-4422(15)00393-2 pmid:26822746

   CrossRefPubMed
8. 8.↵
   1. Winter A,
   2. Chwalisz B

   . MRI characteristics of NMO, MOG and MS related optic neuritis. Semin Ophthalmol 2020;35:333–42 doi:10.1080/08820538.2020.1866027 pmid:33395326

   CrossRefPubMed
9. 9.↵
   1. Riederer I,
   2. Sollmann N,
   3. Mühlau M, et al

   . Gadolinium-enhanced 3D T1-weighted black-blood MR imaging for the detection of acute optic neuritis. AJNR Am J Neuroradiol 2020;41:2333–38 doi:10.3174/ajnr.A6807 pmid:33122200

   CrossRefPubMed
10. 10.↵
    1. Hodel J,
    2. Outteryck O,
    3. Bocher AL, et al

    . Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study. Eur Radiol 2014;24:3069–75 doi:10.1007/s00330-014-3342-3 pmid:25149294

    CrossRefPubMed
11. 11.↵
    1. Bossuyt PM,
    2. Reitsma JB,
    3. Bruns DE, et al

    ; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015;351:h5527 doi:10.1136/bmj.h5527 pmid:26511519

    CrossRefPubMed
12. 12.↵
    1. Benchoufi M,
    2. Matzner-Lober E,
    3. Molinari N, et al

    . Interobserver agreement issues in radiology. Diagn Interv Imaging 2020;101:639–41 doi:10.1016/j.diii.2020.09.001 pmid:32958434

    CrossRefPubMed
13. 13.↵
    1. Poillon G,
    2. Collin A,
    3. Benhamou Y, et al

    . Increased diagnostic accuracy of giant cell arteritis using three-dimensional fat-saturated contrast-enhanced vessel-wall magnetic resonance imaging at 3 T. Eur Radiol 2020;30:1866–75 doi:10.1007/s00330-019-06536-7 pmid:31811430

    CrossRefPubMed
14. 14.↵
    1. Yang R,
    2. Qu B,
    3. Liu WV, et al

    . Detection of acute optic neuritis using contrast-enhanced 3-dimensional Cube T1-weighted imaging: a preliminary study. Comb Chem High Throughput Screen 2023;26:1480–87 doi:10.2174/1386207325666220823121312 pmid:36017841

    CrossRefPubMed
15. 15.↵
    1. Sommer NN,
    2. Saam T,
    3. Coppenrath E, et al

    . Multiple sclerosis: improved detection of active cerebral lesions with 3-dimensional T1 black-blood magnetic resonance imaging compared with conventional 3-dimensional T1 GRE imaging. Invest Radiol 2018;53:13–19 doi:10.1097/RLI.0000000000000410 pmid:28858894

    CrossRefPubMed
16. 16.↵
    1. Davion JB,
    2. Lopes R,
    3. Drumez É, et al

    . Asymptomatic optic nerve lesions: an underestimated cause of silent retinal atrophy in MS. Neurology 2020;94:e2468–78 doi:10.1212/WNL.0000000000009504 pmid:32434868

    CrossRefPubMed
17. 17.↵
    1. Healy GM,
    2. Redmond CE,
    3. Gaughan M, et al

    . The accuracy of standard multiple sclerosis MRI brain sequences for the diagnosis of optic neuropathy. Mult Scler Relat Disord 2020;38:101521 doi:10.1016/j.msard.2019.101521 pmid:31756609

    CrossRefPubMed
18. 18.↵
    1. Mournet S,
    2. Sené T,
    3. Charbonneau F, et al

    . Early diffusion-weighted MRI at 3 Tesla detects ischemic changes of the optic nerve in anterior ischemic optic neuropathy. Eur Radiol 2022;32:3588–96 doi:10.1007/s00330-021-08417-4 pmid:34851430

    CrossRefPubMed
19. 19.↵
    1. Hur M,
    2. Madhavan AA,
    3. Hodge DO, et al

    . Comparison of 1.5 Tesla and 3.0 Tesla magnetic resonance imaging in the evaluation of acute demyelinating optic neuritis. J Neuroophthalmol 2022;42:297–302 doi:10.1097/WNO.0000000000001559 pmid:35439224

    CrossRefPubMed
20. 20.↵
    1. Piechotta PL,
    2. Bonekamp D,
    3. Sill M, et al

    . Increased delay between gadolinium chelate administration and T1-weighted magnetic resonance imaging acquisition increases contrast-enhancing tumor volumes and T1 intensities in brain tumor patients. Invest Radiol 2018;53:223–28 doi:10.1097/RLI.0000000000000432 pmid:29200014

    CrossRefPubMed
21. 21.↵
    1. Kushnirsky M,
    2. Nguyen V,
    3. Katz JS, et al

    . Time-delayed contrast-enhanced MRI improves detection of brain metastases and apparent treatment volumes. J Neurosurg 2016;124:489–95 doi:10.3171/2015.2.JNS141993 pmid:26361281

    CrossRefPubMed